ABVC BioPharma appoints Dr. Uttam Patil as CEO after Dr. Howard Doong resigns

ABVC BIOPHARMA, INC.

Dr. Howard Doong resigned as CEO effective June 21, 2023; no disagreement with Company operations.
Board appointed Dr. Uttam Yashwant Patil as CEO and President effective June 23, 2023.
Dr. Patil also serves as COO and Scientific Officer of subsidiary BioKey since May 2023.
New employment agreement provides one-year term, salary paid in stock options, and severance in stock shares.
He holds a Ph.D. in Chemistry from National Tsing Hua University and previously served as post-doctoral fellow at NTNU.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Uttam Yashwant Patil

Chief Executive Officer

ABVC · ABVC BIOPHARMA, INC.

Filed: June 23, 2023, 7:59 PM ET

The Company’s board of directors appointed Dr. Uttam Yashwant Patil to replace Dr. Doong as the Company’s CEO.

Departed

Dr. Howard Doong

Chief Executive Officer

ABVC · ABVC BIOPHARMA, INC.

Effective: 2023-06-21
Successor: Dr. Uttam Yashwant Patil
Filed: June 23, 2023, 7:59 PM ET

Dr. Howard Doong, the Chief Executive Officer (“CEO”) of ABVC BioPharma, Inc. (the “Company”), notified the Company of his resignation, effective June 21, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Uttam Yashwant Patil was appointed as Chief Executive Officer at ABVC BIOPHARMA, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

The Company’s board of directors appointed Dr. Uttam Yashwant Patil to replace Dr. Doong as the Company’s CEO.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Howard Doong resigned as Chief Executive Officer at ABVC BIOPHARMA, INC..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Dr. Howard Doong, the Chief Executive Officer (“CEO”) of ABVC BioPharma, Inc. (the “Company”), notified the Company of his resignation, effective June 21, 2023.

View on SEC.gov

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-051347

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.